Key terms
About ATHA
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ATHA news
Apr 15
7:03am ET
Athira Pharma appoints Javier San Martin as Chief Medical Officer
Apr 11
7:07am ET
Athira Pharma announces publication of preclinical data on fosgonimeton
Mar 08
7:05am ET
Athira Pharma presents clinical, preclinical data of fosgonimeton
Feb 28
12:10am ET
Analysts Are Bullish on These Healthcare Stocks: Athira Pharma (ATHA), BeiGene (BGNE)
Feb 23
12:15am ET
Favorable Outlook for Athira Pharma with Strong Trial Progress and Robust Financials Prompting a ‘Buy’ Rating
Feb 22
6:55pm ET
Goldman Sachs Sticks to Their Hold Rating for Athira Pharma (ATHA)
Feb 22
4:26pm ET
Athira Pharma Launches New Equity Incentive Plan for Talent
Feb 22
4:20pm ET
Athira Pharma reports FY23 EPS ($3.09), consensus ($3.33)
Feb 15
11:56am ET
2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)
Feb 08
4:05pm ET
Athira Pharma publishes research highlighting ATH-1105
Jan 22
2:01pm ET
Analysts’ Top Healthcare Picks: Petros Pharmaceuticals (PTPI), Athira Pharma (ATHA)
No recent press releases are available for ATHA
ATHA Financials
Key terms
Ad Feedback
ATHA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ATHA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range